{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:47:20Z","timestamp":1793310440064,"version":"4.5.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Rheumatoid arthritis (RA) is an inflammatory disease whose clinical phenotype largely depends on the presence of rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA). Seronegative RA appears to be a less severe disease, but this remains controversial. This study aimed to assess whether seronegative patients show a less severe disease than seropositive patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A cross-sectional study was conducted on RA outpatients from a single center. Clinical activity scales, laboratory evaluations, and cardiovascular risk scores were assessed. Musculoskeletal ultrasound (US) examinations were performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred and fourteen patients were enrolled. Eighty-five were seropositive (76% women) and 29 seronegative (93% women). Seropositive patients had a younger age at disease onset (43 \u00b1 14 vs. 54 \u00b1 11; <jats:italic>p<\/jats:italic> = 0.001) and used sulfasalazine (47 vs. 17%; <jats:italic>p<\/jats:italic> = 0.004) and glucocorticoids (36 vs. 10%; <jats:italic>p<\/jats:italic> = 0.007) more frequently. No differences in clinical activity scales and in 10-year cardiovascular risk were observed. Pathological US data were found more frequently in seropositive patients in the 2<jats:sup>nd<\/jats:sup> metacarpophalangeal (MCP) joint, both in grayscale (71 vs. 38%; <jats:italic>p<\/jats:italic> = 0.008) and in power Doppler (PD; 53 vs. 9%; <jats:italic>p<\/jats:italic> &amp;lt; 0.001); erosions (36 vs. 9%; <jats:italic>p<\/jats:italic> = 0.020) were also more frequent. We found greater severity of PD signals in the 2nd MCP and 3rd MCP joints of the seropositive patients, while synovitis severity was higher only in the 2nd MCP joints. The percentage of total joints with erosions (9 vs. 1%; <jats:italic>p<\/jats:italic> &amp;lt; 0.001) and 2nd MCP joints with erosions (25 vs. 7%; <jats:italic>p<\/jats:italic> &amp;lt; 0.001) was higher in seropositive patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>RA patients show a differentiated phenotype according to their ACPA and RF status. In seronegative patients, RA begins later in life and has a lower requirement for antirheumatic therapies. On US evaluation, seropositive patients show more joint damage, especially in MCP joints. Despite this, long-term cardiovascular risk is similar among RA patients, regardless of their RF and ACPA status.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.978351","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T05:30:41Z","timestamp":1660627841000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Patients with seronegative rheumatoid arthritis have a different phenotype than seropositive patients: A clinical and ultrasound study"],"prefix":"10.3389","volume":"9","author":[{"given":"Natalia","family":"Carbonell-Bobadilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Soto-Fajardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"Amezcua-Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Beatriz","family":"Batres-Marroqu\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Hern\u00e1ndez-Diazcouder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Jim\u00e9nez-Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Cristina","family":"Medina-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis H.","family":"Silveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3899\/jrheum.100951","article-title":"Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology","volume":"86","author":"Pel\u00e1ez-Ballestas","year":"2011","journal-title":"J Rheumatol Suppl"},{"key":"B2","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1136\/ard.2006.051391","article-title":"Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review","volume":"65","author":"Avouac","year":"2005","journal-title":"Ann Rheum Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/acr.20207","article-title":"Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies","volume":"62","author":"Farragher","year":"2010","journal-title":"Arthritis Care Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1136\/annrheumdis-2015-208873","article-title":"Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-na\u00efve patients classified according to the 2010 ACR\/EULAR criteria","volume":"76","author":"Nordberg","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1007\/s00296-011-2329-5","article-title":"A comparative study on the diversity of clinical features between the sero-negative and sero-positive rheumatoid arthritis patients","volume":"32","year":"2012","journal-title":"Rheumatol Int."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0199468","article-title":"Clinical management of seronegative and seropositive rheumatoid arthritis: a comparative study","volume":"13","author":"Choi","year":"2018","journal-title":"PLoS ONE."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/acr.23171","article-title":"Incidence and prevalence of cardiovascular risk factors among patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis","volume":"69","author":"Radner","year":"2017","journal-title":"Arthritis Care Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1136\/ard.2006.059980","article-title":"Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?","volume":"67","author":"Gonzalez","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1136\/annrheumdis-2013-204715","article-title":"The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis","volume":"73","author":"Zhang","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/art.22482","article-title":"HLA\u2013DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis","volume":"57","author":"Gonzalez-Gay","year":"2007","journal-title":"Arthritis Rheum."},{"key":"B11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/art.38210","article-title":"Erikson JM, Escalante A. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis","volume":"66","author":"Battafarano","year":"2014","journal-title":"Arthritis Rheum."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1002\/acr.22296","article-title":"Mortality trends in patients with early rheumatoid arthritis over 20 years: results from the norfolk arthritis register","volume":"66","author":"Humphreys","year":"2014","journal-title":"Arthritis Care Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/0003319710373749","article-title":"Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis?","volume":"62","author":"Toms","year":"2011","journal-title":"Angiology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk","volume":"63","author":"Goff","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World medical association declaration of Helsinki","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/art.23529","article-title":"Validity, reproducibility, and responsiveness of a twelve-joint simplified power doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis","volume":"59","author":"Naredo","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1136\/annrheumdis-2017-211585","article-title":"The 2017 EULAR standardised procedures for ultrasound imaging in rheumatology","volume":"76","author":"M\u00f6ller","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3899\/jrheum.181095","article-title":"OMERACT definitions for ultrasonographic pathologies and elementary lesions of rheumatic disorders 15 years on","volume":"46","author":"Bruyn","year":"2019","journal-title":"J Rheumatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e000428","DOI":"10.1136\/rmdopen-2016-000428","article-title":"Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce \u2014 Part 1: definition and development of a standardised, consensus-based scoring system","volume":"3","author":"D'Agostino","year":"2017","journal-title":"RMD Open."},{"key":"B21","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13075-019-1909-8","article-title":"Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort","volume":"21","author":"Mouterde","year":"2019","journal-title":"Arthritis Res Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.3899\/jrheum.140082","article-title":"Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis","volume":"41","author":"Barra","year":"2014","journal-title":"J Rheumatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1136\/ard.2009.113092","article-title":"Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study","volume":"69","author":"Syversen","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.3899\/jrheum.121438","article-title":"Should we redefine treatment targets in rheumatoid arthritis? Low disease activity is sufficiently strict for patients who are anticitrullinated protein antibody-negative","volume":"40","author":"De Punder","year":"2013","journal-title":"J Rheumatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1136\/rmdopen-2018-000752","article-title":"Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR\/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial","volume":"4","author":"Nordberg","year":"2018","journal-title":"RMD Open."},{"key":"B26","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.atherosclerosis.2013.02.009","article-title":"Antibodies to citrullinated peptides and risk of coronary heart disease","volume":"228","author":"Cambridge","year":"2013","journal-title":"Atherosclerosis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jcdr.2012.09.003","article-title":"Anti-CCP antibody in patients with established rheumatoid arthritis: does it predict adverse cardiovascular profile?","volume":"4","author":"Arnab","year":"2013","journal-title":"J Cardiovasc Dis Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/art.20878","article-title":"Cardiovascular death in rheumatoid arthritis: a population-based study","volume":"52","author":"Maradit-Kremers","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.3899\/jrheum.090188","article-title":"Autoantibodies and the risk of cardiovascular events","volume":"36","author":"Liang","year":"2009","journal-title":"J Rheumatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"960","DOI":"10.55563\/clinexprheumatol\/so5skx","article-title":"Proliferative synovitis, an ultrasound pattern associated with ACPA-positive patients and erosive disease in rheumatoid arthritis","volume":"40","author":"Ram\u00edrez","year":"2022","journal-title":"Clin Exp Rheumatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00296-019-04492-5","article-title":"ACPA-positive versus ACPA-negative rheumatoid arthritis: two distinct erosive disease entities on radiography and ultrasonography","volume":"40","author":"Grosse","year":"2020","journal-title":"Rheumatol Int."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.978351\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T05:30:51Z","timestamp":1660627851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.978351\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":31,"alternative-id":["10.3389\/fmed.2022.978351"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.978351","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,16]]},"article-number":"978351"}}